Literature DB >> 11907131

Oligoclonal T cell expansion in the skin of patients with systemic sclerosis.

Lazaros I Sakkas1, Bin Xu, Carol M Artlett, Song Lu, Sergio A Jimenez, Chris D Platsoucas.   

Abstract

Fibrosis, microvascular fibroproliferative alterations, and autoantibody production are the main features of systemic sclerosis (SSc), and all of them can be explained by cytokine production by activated T cells. However, little is known about the role of T cells in the pathogenesis of SSc, and there is no information on the Ag(s) that elicits such activation. To determine whether T cells infiltrating the skin biopsies of patients with SSc are oligoclonal, beta-chain TCR transcripts from T cells infiltrating the skin of five patients with SSc of recent onset were amplified by either Vbeta-specific PCR or nonpalindromic adaptor PCR. The resulting PCR products were subsequently cloned and sequenced. High proportions of identical beta-chain TCR transcripts ranging from 43 to 90% of those sequenced were found in five patients, strongly suggesting the presence of oligoclonal T cells in these infiltrates. A dominant T cell clone was found to be clonally expanded in skin biopsies obtained from a single patient with SSc at three different times (0, 8, and 13 mo earlier) and from three different skin regions. beta-chain TCR transcripts from PBMC from normal donors (methodological control) were unique when compared with each other, typical for polyclonal populations of T cells. The finding of oligoclonal T cells infiltrating the skin of patients with SSc suggests that these T cells have undergone proliferation in situ in the skin and clonal expansion in response to as yet unidentified Ag(s). These results suggest that T cells are involved in the pathogenesis of the disease.

Entities:  

Mesh:

Year:  2002        PMID: 11907131     DOI: 10.4049/jimmunol.168.7.3649

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  61 in total

1.  Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry.

Authors:  D Farge; J Passweg; J M van Laar; Z Marjanovic; C Besenthal; J Finke; H H Peter; F C Breedveld; W E Fibbe; C Black; C Denton; I Koetter; F Locatelli; A Martini; A V N Schattenberg; F van den Hoogen; L van de Putte; F Lanza; R Arnold; P A Bacon; S Bingham; F Ciceri; B Didier; J L Diez-Martin; P Emery; W Feremans; B Hertenstein; F Hiepe; R Luosujärvi; A Leon Lara; A Marmont; A M Martinez; H Pascual Cascon; C Bocelli-Tyndall; E Gluckman; A Gratwohl; A Tyndall
Journal:  Ann Rheum Dis       Date:  2004-08       Impact factor: 19.103

Review 2.  Immunomodulatory therapy for SSc: will high-intensity immunosuppression with stem cell rescue improve outcome?

Authors:  Leslie J Crofford
Journal:  Curr Rheumatol Rep       Date:  2005-04       Impact factor: 4.592

Review 3.  T cells and B cells in the pathogenesis of systemic sclerosis: recent insights and therapeutic opportunities.

Authors:  Francesco Del Galdo; Carol M Artlett
Journal:  Curr Rheumatol Rep       Date:  2006-04       Impact factor: 4.592

4.  Targeting activated T cells: successful use of anti-CD25 monoclonal antibody basiliximab in a patient with systemic sclerosis.

Authors:  H U Scherer; G-R Burmester; G Riemekasten
Journal:  Ann Rheum Dis       Date:  2006-09       Impact factor: 19.103

5.  B cell depletion treatment decreases CD4+IL4+ and CD4+CD40L+ T cells in patients with systemic sclerosis.

Authors:  Ioannis Antonopoulos; Dimitrios Daoussis; Maria-Eleni Lalioti; Theodora E Markatseli; Alexandros A Drosos; Stavros Taraviras; Andrew P Andonopoulos; Stamatis-Nick C Liossis
Journal:  Rheumatol Int       Date:  2019-06-21       Impact factor: 2.631

6.  Peripheral T lymphocytes from patients with early systemic sclerosis co-cultured with autologous fibroblasts undergo an oligoclonal expansion similar to that occurring in the skin.

Authors:  Raffaele De Palma; Francesco Del Galdo; Salvatore Lupoli; Paolo Altucci; Gianfranco Abbate; Gabriele Valentini
Journal:  Clin Exp Immunol       Date:  2006-04       Impact factor: 4.330

Review 7.  The role of the acquired immune response in systemic sclerosis.

Authors:  Carlo Chizzolini; Francesco Boin
Journal:  Semin Immunopathol       Date:  2015-07-08       Impact factor: 9.623

Review 8.  The pathogenesis of systemic sclerosis revisited.

Authors:  Matthias Geyer; Ulf Müller-Ladner
Journal:  Clin Rev Allergy Immunol       Date:  2011-04       Impact factor: 8.667

9.  A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease.

Authors:  Arnold E Postlethwaite; Weng Kee Wong; Philip Clements; Soumya Chatterjee; Barri J Fessler; Andrew H Kang; Joseph Korn; Maureen Mayes; Peter A Merkel; Jerry A Molitor; Larry Moreland; Naomi Rothfield; Robert W Simms; Edwin A Smith; Robert Spiera; Virginia Steen; Kenneth Warrington; Barbara White; Frederick Wigley; Daniel E Furst
Journal:  Arthritis Rheum       Date:  2008-06

10.  T cell polarization identifies distinct clinical phenotypes in scleroderma lung disease.

Authors:  Francesco Boin; Umberto De Fanis; Susan J Bartlett; Fredrick M Wigley; Antony Rosen; Vincenzo Casolaro
Journal:  Arthritis Rheum       Date:  2008-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.